Skip to content
  • twitter
  • linkedin
  • onxeo
  • SUBSCRIBE TO OUR NEWS
  • EN
  • FR
  • CONTACT
Onxeo

Onxeo

Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.

  • COMPANY
    • Profile
    • Management
    • Board of Directors
    • Join us
    • Contact us
  • SCIENCE
    • Scientific Advisory Committee
    • DNA Damage Response
    • platON™
    • Collaborations
  • PRODUCTS
    • DDR Pipeline
    • AsiDNA™
    • OX401
    • Other
  • INVESTORS
    • Regulated Information
      • Press Releases
      • Registration documents
      • Financial Information
      • Shares & Voting Rights
      • Share Repurchase/ Liquidity Agreement
      • Financial operations
      • Sponsor/ Advisor
    • Governance
      • Board Committees & Regulations
      • Directors’ Disclosures
      • Bylaws
    • Shareholder Resources
      • General Meetings
      • Financial Calendar
      • Stock Information
      • Shareholders’ Letters
    • Investor Relations
  • NEWS & EVENTS
    • Press Releases
    • Events & Presentations
    • Shareholder Letters
    • Media

Category: General meetings

Combined General Meeting of May 29, 2020 in Camera

Shareholders’ Combined General Meeting of May 29,  2020 in Camera   Access the Managment Presentation to the General Meeting of […]

Extraordinary General Meeting in camera on 2nd call

Extraordinary General Meeting of 19 June 2020 in camera on 2nd call The Extraordinary General Meeting was held on second […]

Onxeo’s Joint General Meeting in camera on May 29, 2020: availability of preparatory documents and live webcast login information

05/07/202005/07/2020

Paris (France), May 7, 2020 – 7:30 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

Combined General Meeting on May 16, 2018

04/25/201810/04/2019

Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]

Passing on Onxeo’s Extraordinary and Ordinary General Meeting

04/06/201610/03/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]

BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions

04/08/201409/11/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Annual General Shareholders’ Meeting 2015: Results and convening to a new Meeting

04/15/201509/06/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhague : ONXEO), société innovante spécialisée dans le développement de médicaments orphelins en oncologie, informe ses […]

Combined Ordinary and Extraordinary General Meeting on April 15, 2015: Procedures for obtaining preparatory documents

03/25/201509/06/2019

Onxeo’s shareholders are invited to attend the Combined Ordinary and Extraordinary General Meeting to be held at 9:30am on April […]

Onxeo’s Combined General Meeting of Shareholders 2015

05/20/201509/06/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced […]

Onxeo Ordinary and Extraordinary General Meeting on April 6, 2016

03/16/201609/06/2019

Paris (France), Copenhagen (Denmark) –  Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]

Combined General Meeting on April 26, 2017

04/05/201709/06/2019

Paris (France), April 5, 2017 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]

Annual General Meeting of April 26, 2017

04/26/201709/06/2019

All ordinary resolutions approved Two new independent directors appointed Renewal of the terms of office of Mrs Judith Greciet, CEO, […]

Annual General Meeting of May 16, 2018

05/16/201809/06/2019

Approval of all ordinary resolutions Renewal of the terms of office of Mr. Thomas Hofstaetter Notice of a new Extraordinary […]

Ordinary General Meeting on April 26, 2019

04/05/201909/06/2019

Paris (France), April 5, 2019 – 10 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]

Ordinary General Meeting of May 22, 2019

05/22/201909/04/2019

Renewal of the terms of office of Danièle Guyot-Caparros, Jean-Pierre Bizzari and Jean-Pierre Kinet Appointment of Danièle Guyot-Caparros as Chairman […]

NEWS & EVENTS

  • Press Releases
  • Events & Presentations
  • Shareholder Letters
  • Media
Onxeo

> SITE MAP

> LEGAL NOTICES
> FOLLOW US

COMPANY

COMPANY


  • Profile
  • Executive Committee
  • Board of Directors
  • Join us
  • Contact us

SCIENCE

SCIENCE


  • DNA Damage Response
  • platON™
  • Collaborations

PRODUCTS

PRODUCTS


  • Pipeline
  • AsiDNA™
  • OX401
  • belinostat / Beleodaq®

INVESTORS

INVESTORS


  • Regulated Information
  • Governance
  • Shareholder Resources
  • Investor Relations

NEWS AND EVENTS

NEWS & RELEASES


  • Press Releases
  • Events & Presentations
  • NewsLetters
  • Media
SUBSCRIBE TO
OUR NEWS
CONTACT
US

ONXEO SA


49, avenue du Général Martial Valin
75015 PARIS – FRANCE
+33 (0) 1 45 58 76 00

185 Alewife Brook Parkway
Suite 210, Cambridge, MA 02138
(617) 648-8674

© Copyright 2019 Onxeo
Photos : Onxeo - Design : 1sur1.net

Copyright © 2023 Onxeo All rights reserved. Theme: Flash by ThemeGrill. Powered by WordPress